FDA clinical hold on the LAPC program
The planned pancreatic cancer trial cannot proceed until requested studies and responses are accepted.
- Scope
- Lead product candidate development
- Materiality
- high
PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a U.S.-based biotechnology company focused on developing cellular therapies for cancer using its proprietary Cell-in-a-Box® live-cell encapsulation platform. The company’s current product candidate family includes CypCaps™, with development centered on therapies for pancreatic cancer and other oncology indications.
45.28
12.33
| % | |
|---|---|
| Cellular therapy platform | 70% Encapsulated live-cell technologies designed to activate cancer prodrugs near tumors. |
| Lead oncology product candidate | 20% CypCaps™ and related encapsulated-cell product candidates for pancreatic cancer. |
| Preclinical and translational development | 10% Research, assay development, and nonclinical work supporting IND-enabling studies. |
PharmaCyte Biotech does not currently sell commercial products; its primary counterparties are regulators, clinical...
- Regulatory authoritiesprimary
FDA and comparable agencies review INDs, clinical holds, and trial packages for the company's oncology programs.
- Clinical investigators and trial sitesprimary
Hospitals, physicians, and research sites conduct preclinical and clinical studies for LAPC and related programs.
- Potential licensing partnerssecondary
Large pharmaceutical companies may license approved product candidates for commercialization.
- Future oncology patientsemerging
Patients with pancreatic cancer and other cancers would be treated if the therapies reach market.
The company is headquartered in Las Vegas, Nevada and is incorporated in the United States. Its business is primarily U...
- •Headquartered in Las Vegas, Nevada
- •Incorporated in Nevada, United States
- •Primary regulatory exposure is to the FDA and U.S. healthcare laws
- •Clinical development is centered on U.S.-based oncology programs
- •Future commercialization could extend to Europe through EMA pathways
The company’s strategy is to advance its Cell-in-a-Box® platform through regulatory clearance and clinical development...
01
Clear the FDA clinical hold on LAPCshort-term
Regulatory clearance is required before the planned pancreatic cancer trial can proceed.
02
Advance the Cell-in-a-Box® oncology platformmedium-term
The platform is the core technology underpinning the company's product candidates.
03
Preserve commercialization flexibilitymedium-term
The company may need a licensing or partnership route to bring any approved therapy to market.
PharmaCyte Biotech faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays,...
Dependence on SG Austria technology and know-how
The company disclosed that licensed patents have expired and know-how resides with SG Austria.
- Scope
- Core platform access
- Materiality
- high
Clinical and preclinical failure
Oncology programs may fail to show safety, efficacy, or manufacturability in trials.
- Scope
- Product candidate pipeline
- Materiality
- high
Dilution and financing risk
The company expects to need additional capital and may rely on equity, debt, or partnerships.
- Scope
- Corporate funding
- Materiality
- high
Biologics manufacturing complexity
Cell-based products require specialized facilities, quality controls, and validated processes.
- Scope
- Cell encapsulation and fill-finish steps
- Materiality
- medium
Nasdaq listing compliance risk
A sustained low share price could lead to delisting and reduce liquidity for investors.
- Scope
- Public market access
- Materiality
- medium
Fair value of financial instruments
Can affect reported gains, losses, and balance sheet values
Impairment of indefinite-lived intangible assets
Can create non-cash charges and reduce asset carrying values
Stock-based compensation
Can materially affect operating expenses and net loss
Related-party service agreements
Requires careful disclosure and expense classification
No revenue and development-stage expense profile
Quarterly comparability is driven by project timing rather than sales seasonality
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
VERACYTE, INC.
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
INCYTE CORP
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
MAXCYTE, INC.
MXCT · Services-Commercial Physical & Biological Research
MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family.
Greenwich LifeSciences, Inc.
GLSI · Pharmaceutical Preparations
PRECIGEN, INC.
PGEN · Pharmaceutical Preparations
: 29/04/2026